Business
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
New patents granted in 2025 in Australia and Japan bolster global IP coverage for Aprea’s WEE1 and ATR programs. Core patent families are expected to provide exclusivity into 2045. Lead WEE1 inhibitor candidate APR-1051 is advancing in Phase 1 trials, with early clinical proof of concept demonstrated and multiple 2026 data readouts anticipated Broad intellectual property protection and ongoing clinical progress position Aprea for long-term value creation DOYLESTOWN, Pa., Feb. 12, 2026 (GLOBE NEW
About this update from Aprea Therapeutics, Inc.
[{"type":"image","alt":"Aprea Therapeutics","displaySize":"","headline":null,"caption":"Aprea Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/99b3e900fb935fcf64456ae36360cec0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bNZPaglg_h8I4EDLnMTyIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/99b3e900fb935fcf64456ae36360cec0","width":300,"height":73}},"lazy":false},{"type":"text","content":"New patents granted in 2025 in Australia and Japan bolster global IP coverage for Aprea’s WEE1 and ATR programs. Core patent families are expected to provide exclusivity into 2045.","length":180,"tagName":"p"},{"type":"text","content":"Lead WEE1 inhibitor candidate APR-1051 is advancing in Phase 1 trials, with early clinical proof of concept demonstrated and multiple 2026 data readouts anticipated","length":164,"tagName":"p"},{"type":"text","content":"Broad intellectual property protection and ongoing clinical progress position Aprea for long-term value creation","length":112,"tagName":"p"},{"type":"text","content":"DOYLESTOWN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced significant recent expansions of its global intellectual property estate supporting its DDR-focused oncology pipeline.","length":415,"tagName":"p"},{"type":"text","content":"Aprea’s patent strategy is designed to secure durable global protection around its proprietary molecules, formulations, and therapeutic applications, to de-risk clinical development and maximize long-term commercial value.","length":222,"tagName":"p"},{"type":"text","content":"“Our intellectual property estate is a foundational asset for Aprea and a key component of our long-term strategy to create value and differentiate Aprea within the DDR therapeutics field,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. “We are building a broad, defensible portfolio across both our WEE1 and ATR programs, strengthened by multiple new patents granted in 2025 in key global markets. This portfolio is designed to protect our core ...